These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39632107)

  • 1. Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.
    Zhang PF; Zhang WH; Liu XJ; He D; Yang K; Gou HF; Hu JK
    BMJ Open; 2024 Dec; 14(12):e081529. PubMed ID: 39632107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial.
    Zhang PF; Chen Y; Li WK; Luo ZM; Chen J; Qian K; Chen XD; Wang MJ; Liu M
    Front Immunol; 2024; 15():1431957. PubMed ID: 39606219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
    Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F
    Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
    Gao X; Ji K; Jia Y; Shan F; Chen Y; Xu N; Jia Z; Liu T; Yang N; Zhong H; Li C; Guo Z; Fan Q; Lin X; Zhang Y; Ren H; Yang H; Yao Z; Liu W; Wang ZM; Li B; Xia M; Shen L; Li Z; Ji J
    Nat Med; 2024 Jul; 30(7):1943-1951. PubMed ID: 38778212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.
    Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H
    JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
    Jiang Z; Xie Y; Zhang W; Du C; Zhong Y; Zhu Y; Jiang L; Dou L; Shao K; Sun Y; Xue Q; Tian Y; Gao S; Zhao D; Zhou A
    Gastric Cancer; 2024 May; 27(3):571-579. PubMed ID: 38457083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
    Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
    Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.
    Jiang H; Sun N; Li R; Guan W; Zhu Y; Xie Z; Xie X; Liu M; Lin X; Zhou C
    Clin Lung Cancer; 2024 Dec; 25(8):e393-e396. PubMed ID: 39095236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short-term efficacy and safety of neoadjuvant Sintilimab combined with chemotherapy for resectable gastroesophageal junction adenocarcinoma.
    Chen L; Zhang S; Ma H; Zhong K; Yang D; Sun J; Liu H; Song R; Cai H
    Langenbecks Arch Surg; 2024 Dec; 410(1):5. PubMed ID: 39666161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
    Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
    Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
    Liu SL; Li XY; Yang JH; Wen DX; Guo SS; Liu LT; Li YF; Luo MJ; Xie SY; Liang YJ; Sun XS; Yang ZC; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Lan KQ; Jia GD; Li R; Zhao C; Xu RH; Chen QY; Tang LQ; Mai HQ
    Lancet Oncol; 2024 Dec; 25(12):1563-1575. PubMed ID: 39522541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.
    Dreyer MS; Mulcahy M; Kocherginsky M; Chen Y; Hochster HS; Kasi PM; Kircher S; Lou E; Ma Y; Uboha NV; Benson AB
    Oncologist; 2024 Dec; 29(12):1044-1050. PubMed ID: 39293067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study.
    Yin L; Jiang W; Liu S; Fu Y; Zhou L; Pei X; Ye S; Shen W; Yang H; Shan B
    BMC Med; 2024 Oct; 22(1):496. PubMed ID: 39468597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative systemic therapy as a part of comprehensive multimodal treatment in esophageal and gastric cancer - new treatment guidelines.
    Lordick Obermannová R; Jedlička V; Dvorský J; Sokop T; Grell P; Slavik M; Trna J; Kunovský- L; Kiss I
    Rozhl Chir; 2024; 103(11):443-453. PubMed ID: 39645403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.